Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
AXQ Capital LP Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN
04:07am, Sunday, 23'rd Nov 2025
AXQ Capital LP lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 123.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Ex
What Moved Markets This Week
06:50am, Saturday, 22'nd Nov 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
Dow Jones Today: Stocks Rise to End Down Week; Fed's Williams Signals Support for December Rate Cut
12:01pm, Friday, 21'st Nov 2025
Stocks advanced to end a week that has seen major equities indexes sell off on concerns about AI spending and valuations of big tech firms, while the price of bitcoin continued to fall.
This Month's Stock Trend Hasn't Been AI. Here's What's Been Climbing Instead
11:05am, Friday, 21'st Nov 2025
November's Wall Street obsession hasn't been AI. It's been healthcare.
Market Today: Nvidia (NVDA) Whipsaw, Walmart (WMT) Beats; Fed Cut Odds Fade
05:34pm, Thursday, 20'th Nov 2025
Guru Stock PicksTweedy Browne has made the following transactions:Reduce in CSCO by 2.83%Sold out in HPKAdd in CROX by 105.33%New position in ALSNStock News AI-
Dow, Nasdaq Up Triple Digits as Nvidia Sparks Tech Rally
12:10pm, Thursday, 20'th Nov 2025
The Dow and Nasdaq are sporting triple-digit midday leads after upbeat earnings from Walmart (WMT) and Nvidia (NVDA)
Regeneron Wins FDA Nod For Eylea HD With Reduced Injection Schedule For Patients With Vision Loss
11:52am, Thursday, 20'th Nov 2025
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.'s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following retin
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
10:21am, Thursday, 20'th Nov 2025
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
First Look: Nvidia beats, Walmart lifts outlook, Gemini 3 debuts
07:37am, Thursday, 20'th Nov 2025
Stock News Nvidia crushes Q3 and guides higher: Nvidia (NVDA) reported record Q3 FY26 revenue of $57.0B (+62% y/y) and guided Q4 sales to $65B, citing âoff th
Bronte Capital Management Pty Ltd. Buys 33,177 Shares of Regeneron Pharmaceuticals, Inc. $REGN
04:05am, Thursday, 20'th Nov 2025
Bronte Capital Management Pty Ltd. lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) by 21.4% during the second quarter, according to its most recent 13F filing with the SEC. The inst
First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period
Approval based on results of landmark Phase 3 C-POST trial that show Libtayo is first immunotherapy to significantly improve disease-free survival in CSCC in the adjuvant setting, reducing the risk of
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies London Healthcare Conference 2025 Transcript
01:07pm, Monday, 17'th Nov 2025
Regeneron Pharmaceuticals, Inc. ( REGN ) Jefferies London Healthcare Conference 2025 November 17, 2025 10:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Stra
Regeneron Pharmaceuticals, Inc. (REGN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
11:57am, Monday, 17'th Nov 2025
Regeneron Pharmaceuticals, Inc. ( REGN ) 7th Annual Wolfe Research Healthcare Conference November 17, 2025 9:20 AM EST Company Participants Mark Hudson - Investor Relations Executive Isreal Lowy - Sen
Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this set
